At the 2009 World Molecular Imaging Congress (WMIC) in Montreal, Aspect Magnet Technologies and Bruker BioSpin, a division of Bruker Corporation (NASDAQ: BRKR), today announced that they have signed a Memorandum of Understanding (MoU) for the development of a high performance desktop preclinical MRI system. The new MRI scanner will benefit from the combination of Aspect’s innovative 1 Tesla (T) permanent magnet system and Bruker BioSpin’s high-performance MRI spectrometer technology and its routine preclinical software package.

The new system is expected to enable scientists to explore new fields of preclinical MRI research, such as hyperpolarization, functional applications and contrast agent imaging, all supported by high-resolution MRI morphology imaging. Both companies will evaluate the potential new markets and their technological and applications requirements.

Uri Rapoport, Aspect’s CEO, stated: ”Aspect sees the collaboration with Bruker BioSpin as a major step forward for Aspect, and a recognition of Aspect’s breakthrough technology. I’m sure that there is a very large potential for introducing a 1T permanent magnet MRI system in the fields of contrast agent usage and development of hyperpolarization applications. The intended collaboration between Aspect and Bruker will yield very innovative and productive solutions.”

Dr. Wulf-Ingo Jung, Managing Director of Bruker BioSpin MRI GmbH, commented: “High performance desktop MRI systems have the potential to deliver new research applications to the field of preclinical and molecular imaging. The planned combined system is aimed at easy, routine MRI workflow with a compact footprint, low running costs, no magnetic stray fields outside the magnet, and remarkable push-button imaging performance, based on the latest Bruker spectrometer and software technology, in order to enable new research groups to enter this fascinating field of MRI.”

About Aspect - Aspect Magnet Technologies Ltd. designs, develops and manufactures innovative, compact-size high-resolution Magnetic Resonance Imaging (MRI) based systems for the pre-clinical market performing in-vivo small animal imaging and in-vitro studies. The company’s innovative MRI system will also provide medical applications for human extremities such as Carpal Tunnel Syndrome. Aspect’s breakthrough technology solves many drawbacks in performance in today's MRI market, such as very high unit cost, high cost of ownership, complex operation & installation. Aspect's MRI systems are designed and optimized for the best performance according to the user's budget & needs. Aspect vision is to see MRI used routinely, by producing high performance, high resolution, easy to use and environmentally friendly MRI systems that are affordable to all.

About Bruker BioSpin

For more information about Bruker BioSpin and Bruker Corporation, please visit www.bruker-biospin.com and www.bruker.com.

BRUKER CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2008, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements other than as required by law.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6056580&lang=en

Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Bruker Charts.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Bruker Charts.